Who We Are
The WeCan Study is an effort of Multidisciplinary Association for Psychedelic Studies (MAPS). This research is being conducted by Principal Investigator Dr. Sue Sisley at the Scottsdale Research Institute (SRI). Our mission is to collect objective information about the efficacy of cannabis-based treatments for PTSD and other disorders.
In Cooperation With
The Food and Drug Administration
Drug Enforcement Administration
National Institute on Drug Abuse
Colorado Dept. of Health & Environment
Multidisciplinary Association for Psychedelic Studies
National American Legion
Scottsdale Research Institute
How We Protect Your Privacy
All information that you give will be kept strictly confidential, and the study has received a certificate of confidentiality from the FDA. The information collected about you will not directly identify you. Instead, a code number will be used for your information. This is a federally authorized study.
Your participation WILL NOT affect your VA benefits.
Your records may be reviewed by:
- The study sponsor.
- People who work with the sponsor on the study.
- Government agencies, such as the FDA.
- Copernicus Group Independent Review Board (IRB). The IRB is a group of scientists and non-scientists who review the ethics of research. The goal of the IRB is to protect the rights and welfare of study subjects.
These people may look at your records to make sure the study has been done the right way. They also want to make sure that your health information has been collected the right way, or for other reasons that are allowed under the law.
If information about this study is published, you will not be identified.
WeCan Study Updates
Against the backdrop of the nation’s largest Veterans Day parade, Democratic Gov. Andrew Cuomo announced this month he’d sign legislation making New York the latest in a fast-rising tide of states to OK therapeutic pot as a PTSD treatment, though it’s illegal…
The Cannabist reports on a letter sent by members of the House Committee on Veterans Affairs to the Veterans Administration Secretary David Shulkin, urging the VA to allow research into the efficacy of marijuana for treating symptoms…
Government Executive interviews military veterans who advocate for the use of medical marijuana for treating their symptoms of PTSD. Government Executive highlights MAPS’ ongoing study researching the effects of smoked marijuana as a treatment for…
AP News reports on barriers to access medical marijuana for veterans suffering from PTSD, highlighting MAPS’ ongoing study researching the efficacy of medical marijuana to treat symptoms of PTSD in 76 U.S. veterans. AP News also covers veteran advocacy groups requesting the use of medical marijuana for PTSD and other mental health conditions. “Medical marijuana advocates note it’s been tough to get evidence when testing is complicated by pot’s legal status in the U.S.,” explains Jennifer Peltz of AP News. “[MAPS’] federally approved clinical trial of marijuana as a PTSD treatment for veterans is now underway in Phoenix, and results from the current phase could be ready to submit for publication in a couple of years, says one of the researchers, Dr. Suzanne Sisley.
AP News reports on barriers to access medical marijuana for veterans suffering from PTSD, highlighting MAPS’ ongoing study researching the efficacy of medical marijuana to treat symptoms of PTSD in 76 U.S. veterans.
AP News covers veteran advocacy groups requesting the use of medical marijuana for treating symptoms of PTSD and other mental health conditions.
After seven years of struggling to launch the first government-approved study of marijuana’s effects on veterans with post-traumatic stress disorder, lead researcher Sue Sisley was optimistic in February, when her team was finally allowed…
The Trump administration’s attack on legal marijuana, already stymied by large states determined not to roll back the clock, is increasingly confronting an even more politically potent adversary: military veterans…
Keep up with all the latest news and updates by signing up to our email list.